Table 2.
Summary of outcomes reported in the included RCTs.
| n-3 LCPUFA doses | Studies investigated birth | Studies investigated 0–4 years of age (age of measure) | Studies investigated 5–10 years of age (age of measure) |
|---|---|---|---|
| Weight | |||
| 0–300 mg/day n-3 LCPUFA | Bergmann et al. (59), Van Goor et al. (61), Judge et al. (63), Ostadrahimi et al. (65), Smuts et al. (50), Malcolm et al. (67), Sanjurjo et al. (68) | (21 mohths) Bergmann et al. (59), (18 months) Van Goor et al. (62), (6 months) Ostadrahimi et al. (65) | (6 years) Bergmann et al. (60) |
| 301–650 mg/day n-3 LCPUFA | Ramakrishnan et al. (44), Gonzalez-Casanova et al. (45), Escolano Margarit et al. (54), Campoy et al. (53), Carlson et al. (46), Mulder et al. (48), Harris et al. (49), Keenan et al. (64), Hurtado et al. (66) | (5 years) Gonzalez-Casanova et al. (45), (5 years) Hidaka et al. (47) | |
| More than 650 mg/day n-3 LCPUFA | Makrides et al. (51), Hauner et al. (55), Vinding et al. (57), Helland et al. (69), Olsen et al. (70) | (3 years) Muhlhausler et al. (52), (3 years) Brei et al. (56) | (5 years) Muhlhausler et al. (52), (5 years) Brei et al. (56), (6 years) Vinding et al. (58) (7 years) Helland et al. (69) |
| BMI | |||
| 0–300 mg/day n-3 LCPUFA | Bergmann et al. (59) | (21 mohths) Bergmann et al. (59) | (6 years) Bergmann et al. (60) |
| 301–650 mg/day n-3 LCPUFA | (4 years) Escolano Margarit et al. (54) | (6.5 years) Campoy et al. (53) | |
| More than 650 mg/day n-3 LCPUFA | (3 years) Muhlhausler et al. (52) | (5 years) Muhlhausler et al. (52), (7 years) Helland et al. (69) | |
| BMI z score | |||
| 0–300 mg/day n-3 LCPUFA | (21 months) Bergmann et al. (60) | (6 years) Bergmann et al. (60) | |
| 301–650 mg/day n-3 LCPUFA | (5 years) Gonzalez-Casanova et al. (45), (5 years) Hidaka et al. (47) | ||
| More than 650 mg/day n-3 LCPUFA | (3 years) Muhlhausler et al. (52) | (5 years) Muhlhausler et al. (52), (6 years) Vinding et al. (58) | |
| Circumference (head, arm, Waits) | |||
| 0–300 mg/day n-3 LCPUFA | Judge et al. (63), Ostadrahimi et al., (65), Smuts et al. (50), Malcolm et al. (67) | (18 months) Van Goor et al. (62), (6 months) Ostadrahimi et al. (65) | (6 years) Bergmann et al. (60), |
| 301–650 mg/day n-3 LCPUFA | Ramakrishnan et al. (44), Gonzalez-Casanova et al. (45), Carlson et al. (46), Harris et al. (49), Campoy et al. (53) | ||
| More than 650 mg/day n-3 LCPUFA | Brei et al. (56), Vinding et al. (57) | (3 years) Muhlhausler et al. (52), (3 years) Brei et al. (56) | (5 years) Muhlhausler et al. (52), (5 years) Brei et al. (56), (6 years) Vinding et al. (58) |
| BMI percentile | |||
| More than 650 mg/day n-3 LCPUFA | (3 years) Muhlhausler et al. (52), (3 years) Brei et al. (56) | (5 years) Muhlhausler et al. (52), (5 years) Brei et al. (56) | |
| Fat mass (g)/body fat (%) | |||
| More than 650 mg/day n-3 LCPUFA | Hauner et al. (55) | (3 years) Muhlhausler et al. (52), (3 years) Hauner et al. (55) | (5 years) Muhlhausler et al. (52), (5 years) Hidaka et al. (47)* |
*
n-3 LCPUFA doses: 301–650 mg/day n-3 LCPUFA.
Bold text: intervention groups showed higher result than control groups.